CN103429243A - Cdk抑制剂 - Google Patents
Cdk抑制剂 Download PDFInfo
- Publication number
- CN103429243A CN103429243A CN2011800622979A CN201180062297A CN103429243A CN 103429243 A CN103429243 A CN 103429243A CN 2011800622979 A CN2011800622979 A CN 2011800622979A CN 201180062297 A CN201180062297 A CN 201180062297A CN 103429243 A CN103429243 A CN 103429243A
- Authority
- CN
- China
- Prior art keywords
- alkylidene
- compound
- alkyl
- group
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 COC1N(*)*[n]2c(nc(NC3=CC=C(*)**3)nc3)c3c(*)c12 Chemical compound COC1N(*)*[n]2c(nc(NC3=CC=C(*)**3)nc3)c3c(*)c12 0.000 description 5
- JGYWSLOKJODATI-UHFFFAOYSA-N CC(C(NCC[n]1c2nc(Cl)ncc2cc1C(C)(O)O)O)OC(C)(C)C Chemical compound CC(C(NCC[n]1c2nc(Cl)ncc2cc1C(C)(O)O)O)OC(C)(C)C JGYWSLOKJODATI-UHFFFAOYSA-N 0.000 description 1
- VLIYZHYAQPOVCP-UHFFFAOYSA-N CC(C)(C)OC(NCC1(CCCC1)[n]1c2nc(Cl)ncc2cc1C(O)=O)=O Chemical compound CC(C)(C)OC(NCC1(CCCC1)[n]1c2nc(Cl)ncc2cc1C(O)=O)=O VLIYZHYAQPOVCP-UHFFFAOYSA-N 0.000 description 1
- OUKQMJJNYMRRHN-UHFFFAOYSA-N CC(C)(CN1)[n]2c3nc(Cl)ncc3cc2C1=O Chemical compound CC(C)(CN1)[n]2c3nc(Cl)ncc3cc2C1=O OUKQMJJNYMRRHN-UHFFFAOYSA-N 0.000 description 1
- NJELXXCGCXPBLB-UHFFFAOYSA-N CC(C)C(CN1)[n]2c3nc(Cl)ncc3cc2C1=O Chemical compound CC(C)C(CN1)[n]2c3nc(Cl)ncc3cc2C1=O NJELXXCGCXPBLB-UHFFFAOYSA-N 0.000 description 1
- FGLGSYGXKKYOQJ-UHFFFAOYSA-N CC(C)CC(CN1C)[n]2c3nc(Cl)ncc3cc2C1=O Chemical compound CC(C)CC(CN1C)[n]2c3nc(Cl)ncc3cc2C1=O FGLGSYGXKKYOQJ-UHFFFAOYSA-N 0.000 description 1
- MTZLLBOXBZBQEZ-UHFFFAOYSA-N CC(C)CC(CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br Chemical compound CC(C)CC(CNC(OC(C)(C)C)=O)Nc1nc(Cl)ncc1Br MTZLLBOXBZBQEZ-UHFFFAOYSA-N 0.000 description 1
- NJELXXCGCXPBLB-VIFPVBQESA-N CC(C)[C@H](CN1)[n]2c3nc(Cl)ncc3cc2C1=O Chemical compound CC(C)[C@H](CN1)[n]2c3nc(Cl)ncc3cc2C1=O NJELXXCGCXPBLB-VIFPVBQESA-N 0.000 description 1
- SFMDSWSSZRIVDJ-XPKAQORNSA-N CCC(C)[C@@H](CN1)[n]2c3nc(Nc(cc4)ncc4N4CCNCC4)ncc3cc2C1=O Chemical compound CCC(C)[C@@H](CN1)[n]2c3nc(Nc(cc4)ncc4N4CCNCC4)ncc3cc2C1=O SFMDSWSSZRIVDJ-XPKAQORNSA-N 0.000 description 1
- YVQVMPXTKXNMIV-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)cnc1[N+]([O-])=O Chemical compound CN(CC1)CCN1c(cc1)cnc1[N+]([O-])=O YVQVMPXTKXNMIV-UHFFFAOYSA-N 0.000 description 1
- RHZYTLOZMHUSKU-UHFFFAOYSA-N O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N(CC2)CCC2N2CCOCC2)n1 Chemical compound O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N(CC2)CCC2N2CCOCC2)n1 RHZYTLOZMHUSKU-UHFFFAOYSA-N 0.000 description 1
- UZZZQVCKOLDAMY-UHFFFAOYSA-N O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N2CCCCC2)n1 Chemical compound O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N2CCCCC2)n1 UZZZQVCKOLDAMY-UHFFFAOYSA-N 0.000 description 1
- NLHJLMBCNCNHRL-UHFFFAOYSA-N O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc2ccc(N3CCOCC3)nn2)n1 Chemical compound O=C(c1c2)NCC3(CCCC3)[n]1c1c2cnc(Nc2ccc(N3CCOCC3)nn2)n1 NLHJLMBCNCNHRL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (29)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410184792.2A CN103936745B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201611022263.8A CN106967074A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201610323241.9A CN106008533B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40649810P | 2010-10-25 | 2010-10-25 | |
US61/406,498 | 2010-10-25 | ||
PCT/US2011/057749 WO2012061156A1 (en) | 2010-10-25 | 2011-10-25 | Cdk inhibitors |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410184794.1A Division CN104045654A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201611022263.8A Division CN106967074A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201610323241.9A Division CN106008533B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201410184792.2A Division CN103936745B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103429243A true CN103429243A (zh) | 2013-12-04 |
CN103429243B CN103429243B (zh) | 2016-06-08 |
Family
ID=46024778
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410184794.1A Pending CN104045654A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201611022263.8A Pending CN106967074A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201610323241.9A Active CN106008533B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201410184792.2A Active CN103936745B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201180062297.9A Active CN103429243B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410184794.1A Pending CN104045654A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201611022263.8A Pending CN106967074A (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201610323241.9A Active CN106008533B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
CN201410184792.2A Active CN103936745B (zh) | 2010-10-25 | 2011-10-25 | Cdk抑制剂 |
Country Status (25)
Country | Link |
---|---|
US (2) | US8598186B2 (zh) |
EP (6) | EP3118203B1 (zh) |
JP (4) | JP5923509B2 (zh) |
KR (4) | KR101929593B1 (zh) |
CN (5) | CN104045654A (zh) |
AU (5) | AU2011323739B2 (zh) |
BR (1) | BR112013010018B1 (zh) |
CA (2) | CA2961937C (zh) |
CY (1) | CY1118004T1 (zh) |
DK (1) | DK2632467T3 (zh) |
ES (1) | ES2592515T3 (zh) |
HK (2) | HK1197067A1 (zh) |
HR (1) | HRP20161092T1 (zh) |
HU (1) | HUE030714T2 (zh) |
IL (5) | IL225940A0 (zh) |
LT (1) | LT2632467T (zh) |
MX (4) | MX367795B (zh) |
PL (1) | PL2632467T3 (zh) |
PT (1) | PT2632467T (zh) |
RS (1) | RS55135B1 (zh) |
RU (1) | RU2621674C2 (zh) |
SG (2) | SG189525A1 (zh) |
SI (1) | SI2632467T1 (zh) |
SM (1) | SMT201600311B (zh) |
WO (1) | WO2012061156A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302620A (zh) * | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
CN107383019A (zh) * | 2017-07-28 | 2017-11-24 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3‑h]喹唑啉类化合物及其用途 |
WO2018086591A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
CN108283644A (zh) * | 2013-03-15 | 2018-07-17 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
CN111377924A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | 新型cdk4抑制剂及其用途 |
CN111377935A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | 选择性cdk4/6抑制剂及其应用 |
CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
CN113788837A (zh) * | 2021-08-02 | 2021-12-14 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
CN116157403A (zh) * | 2020-06-15 | 2023-05-23 | G1治疗公司 | 曲拉西利的形态及其制造方法 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
BRPI0915692B8 (pt) | 2008-07-08 | 2021-05-25 | Incyte Corp | compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
AU2011329763A1 (en) | 2010-11-17 | 2013-05-09 | Brigham And Women's Hospital | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
AU2013239816B2 (en) | 2012-03-29 | 2017-08-24 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
JP6435315B2 (ja) * | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
US20140274896A1 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US20160220569A1 (en) * | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
BR112018077155A2 (pt) | 2016-07-01 | 2019-04-02 | G1 Therapeutics, Inc. | processo para preparar um composto, e, composto |
MX2019000200A (es) * | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Agentes antiproliferativos basados en pirimidina. |
WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
IL264950B2 (en) | 2016-08-23 | 2024-01-01 | Eisai R&D Man Co Ltd | Combined treatments for the treatment of malignant liver cell carcinoma |
BR112019005526A2 (pt) | 2016-10-20 | 2019-06-18 | Pfizer | agentes antiproliferativos para tratamento de pah |
US11865176B2 (en) | 2016-11-08 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
EP3585389A4 (en) | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | TREATMENT OF EGFR MEDIATED CANCER WITH LESS SIDE EFFECTS |
IL269357B1 (en) | 2017-03-16 | 2024-06-01 | Eisai R&D Man Co Ltd | A combination of Era inhibitors and a CDK4/6 inhibitor to be used in a method to treat breast cancer |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
KR102659211B1 (ko) | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
CN109985241A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | G1t38の優れた投与レジメン |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
CN112839657A (zh) | 2018-08-24 | 2021-05-25 | G1治疗公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
EP3849537A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US20200316064A1 (en) | 2019-02-15 | 2020-10-08 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4007602A1 (en) | 2019-08-01 | 2022-06-08 | Incyte Corporation | A dosing regimen for an ido inhibitor |
AR119765A1 (es) | 2019-08-14 | 2022-01-12 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
CR20220584A (es) | 2020-04-16 | 2023-02-15 | Incyte Corp | Inhibidores de kras tricíclicos fusionados |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
AU2021273744A1 (en) | 2020-05-19 | 2022-12-08 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
EP4225758A1 (en) * | 2020-10-08 | 2023-08-16 | Teva Pharmaceuticals International GmbH | Solid state forms of trilaciclib and of trilaciclib salts |
WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
KR20240032915A (ko) | 2021-07-07 | 2024-03-12 | 인사이트 코포레이션 | Kras의 저해제로서의 삼환식 화합물 |
US20230114765A1 (en) | 2021-07-14 | 2023-04-13 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
TW202320795A (zh) | 2021-07-26 | 2023-06-01 | 美商凱爾科迪股份有限公司 | 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 |
US20230174555A1 (en) | 2021-08-31 | 2023-06-08 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
AU2022389961A1 (en) | 2021-11-22 | 2024-06-06 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ck12抑制劑 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
US20230192722A1 (en) | 2021-12-22 | 2023-06-22 | Incyte Corporation | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
WO2023116884A1 (en) | 2021-12-24 | 2023-06-29 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
WO2023164255A1 (en) | 2022-02-28 | 2023-08-31 | Teva Pharmaceuticals International Gmbh | Crystalline forms of trilaciclib and trilaciclib salts |
US20230279004A1 (en) | 2022-03-07 | 2023-09-07 | Incyte Corporation | Solid forms, salts, and processes of preparation of a cdk2 inhibitor |
WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
CN115536663A (zh) * | 2022-10-11 | 2022-12-30 | 杭州科巢生物科技有限公司 | 一种曲拉西利中间体及其制备与应用 |
WO2024116069A1 (en) * | 2022-11-28 | 2024-06-06 | Assia Chemical Industries Ltd. | Novel trilaciclib intermediates, method of preparation and use thereof |
CN117069663B (zh) * | 2023-08-31 | 2023-12-26 | 四川维亚本苑生物科技有限公司 | 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052147A2 (en) * | 2003-11-25 | 2005-06-09 | Cyclacel Limited | Method of screening for a modulator of cdk4 |
WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2010020675A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0738717A1 (en) * | 1990-10-09 | 1996-10-23 | Neurogen Corporation | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
CA2470044C (en) * | 2001-12-20 | 2010-12-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
US20050176796A1 (en) * | 2002-02-19 | 2005-08-11 | D'alessio Roberto | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
RS20050944A (en) * | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
EP1678177B1 (en) | 2003-10-23 | 2007-11-28 | F.Hoffmann-La Roche Ag | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
SG177911A1 (en) * | 2006-12-21 | 2012-02-28 | Nerviano Medical Sciences Srl | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
MX2009013897A (es) | 2007-06-25 | 2010-03-30 | Neurogen Corp | Piperacinil oxoalquil tetrahidro-beta-carbolinas y analogos relacionados. |
CN102231983A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
AU2013239816B2 (en) * | 2012-03-29 | 2017-08-24 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
-
2011
- 2011-10-25 KR KR1020137013388A patent/KR101929593B1/ko active IP Right Grant
- 2011-10-25 EP EP16168485.7A patent/EP3118203B1/en active Active
- 2011-10-25 CN CN201410184794.1A patent/CN104045654A/zh active Pending
- 2011-10-25 CN CN201611022263.8A patent/CN106967074A/zh active Pending
- 2011-10-25 CA CA2961937A patent/CA2961937C/en active Active
- 2011-10-25 WO PCT/US2011/057749 patent/WO2012061156A1/en active Application Filing
- 2011-10-25 EP EP21184036.8A patent/EP3981770A1/en not_active Withdrawn
- 2011-10-25 CN CN201610323241.9A patent/CN106008533B/zh active Active
- 2011-10-25 LT LTEP11838545.9T patent/LT2632467T/lt unknown
- 2011-10-25 CA CA2815084A patent/CA2815084C/en active Active
- 2011-10-25 PL PL11838545.9T patent/PL2632467T3/pl unknown
- 2011-10-25 CN CN201410184792.2A patent/CN103936745B/zh active Active
- 2011-10-25 KR KR1020187035510A patent/KR102051881B1/ko active IP Right Grant
- 2011-10-25 MX MX2016004581A patent/MX367795B/es unknown
- 2011-10-25 BR BR112013010018-4A patent/BR112013010018B1/pt active IP Right Grant
- 2011-10-25 SI SI201130943A patent/SI2632467T1/sl unknown
- 2011-10-25 PT PT118385459T patent/PT2632467T/pt unknown
- 2011-10-25 MX MX2020005498A patent/MX2020005498A/es unknown
- 2011-10-25 RU RU2013123790A patent/RU2621674C2/ru active
- 2011-10-25 HU HUE11838545A patent/HUE030714T2/en unknown
- 2011-10-25 SG SG2013031554A patent/SG189525A1/en unknown
- 2011-10-25 SG SG10201508715YA patent/SG10201508715YA/en unknown
- 2011-10-25 KR KR1020207034378A patent/KR20200137048A/ko not_active Application Discontinuation
- 2011-10-25 EP EP15170738.7A patent/EP2955183A1/en not_active Withdrawn
- 2011-10-25 RS RS20160734A patent/RS55135B1/sr unknown
- 2011-10-25 EP EP11838545.9A patent/EP2632467B1/en active Active
- 2011-10-25 JP JP2013535153A patent/JP5923509B2/ja active Active
- 2011-10-25 ES ES11838545.9T patent/ES2592515T3/es active Active
- 2011-10-25 DK DK11838545.9T patent/DK2632467T3/en active
- 2011-10-25 AU AU2011323739A patent/AU2011323739B2/en active Active
- 2011-10-25 KR KR1020197035200A patent/KR102186969B1/ko active IP Right Grant
- 2011-10-25 MX MX2013004681A patent/MX338327B/es active IP Right Grant
- 2011-10-25 CN CN201180062297.9A patent/CN103429243B/zh active Active
- 2011-10-25 EP EP18167945.7A patent/EP3381920B1/en active Active
- 2011-10-25 EP EP19164126.5A patent/EP3567042B1/en active Active
-
2013
- 2013-04-24 US US13/869,520 patent/US8598186B2/en active Active
- 2013-04-24 US US13/869,576 patent/US8598197B2/en active Active
- 2013-04-25 IL IL225940A patent/IL225940A0/en unknown
- 2013-04-25 MX MX2019010602A patent/MX2019010602A/es unknown
-
2014
- 2014-10-23 HK HK14110598A patent/HK1197067A1/zh unknown
-
2015
- 2015-03-05 IL IL237582A patent/IL237582A0/en unknown
- 2015-03-05 IL IL237581A patent/IL237581B/en active IP Right Grant
-
2016
- 2016-04-15 JP JP2016082206A patent/JP6157680B2/ja active Active
- 2016-07-13 AU AU2016204879A patent/AU2016204879B2/en active Active
- 2016-08-26 HR HRP20161092TT patent/HRP20161092T1/hr unknown
- 2016-09-09 SM SM201600311T patent/SMT201600311B/it unknown
- 2016-09-13 CY CY20161100906T patent/CY1118004T1/el unknown
-
2017
- 2017-05-04 IL IL252108A patent/IL252108B/en active IP Right Grant
- 2017-06-02 JP JP2017110115A patent/JP6389926B2/ja active Active
-
2018
- 2018-04-30 AU AU2018202991A patent/AU2018202991B2/en active Active
- 2018-08-17 JP JP2018153563A patent/JP2018193400A/ja not_active Ceased
- 2018-10-18 HK HK18113421.2A patent/HK1254345B/zh unknown
-
2020
- 2020-01-12 IL IL271977A patent/IL271977B/en active IP Right Grant
- 2020-05-07 AU AU2020203035A patent/AU2020203035B2/en active Active
- 2020-05-07 AU AU2020203037A patent/AU2020203037B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052147A2 (en) * | 2003-11-25 | 2005-06-09 | Cyclacel Limited | Method of screening for a modulator of cdk4 |
WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2010020675A1 (en) * | 2008-08-22 | 2010-02-25 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104302620A (zh) * | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
CN108283644A (zh) * | 2013-03-15 | 2018-07-17 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
CN108283644B (zh) * | 2013-03-15 | 2022-03-18 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
CN108699067B (zh) * | 2016-11-11 | 2021-06-15 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
CN108699067A (zh) * | 2016-11-11 | 2018-10-23 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
WO2018086591A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
CN113264935A (zh) * | 2016-11-11 | 2021-08-17 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物及其中间体和医药上的用途 |
US11168088B2 (en) | 2016-11-11 | 2021-11-09 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
CN107383019A (zh) * | 2017-07-28 | 2017-11-24 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3‑h]喹唑啉类化合物及其用途 |
CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
CN111377924A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | 新型cdk4抑制剂及其用途 |
CN111377935A (zh) * | 2018-12-29 | 2020-07-07 | 武汉光谷通用名药物研究院有限公司 | 选择性cdk4/6抑制剂及其应用 |
CN111377935B (zh) * | 2018-12-29 | 2021-06-29 | 武汉光谷通用名药物研究院有限公司 | 选择性cdk4/6抑制剂及其应用 |
CN116157403A (zh) * | 2020-06-15 | 2023-05-23 | G1治疗公司 | 曲拉西利的形态及其制造方法 |
CN113788837A (zh) * | 2021-08-02 | 2021-12-14 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103429243A (zh) | Cdk抑制剂 | |
US10696682B2 (en) | CDK inhibitors | |
EP3555103B1 (en) | Azepane inhibitors of menin-mll interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20131204 Assignee: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd. Assignor: G1 Therapeutics, Inc. Contract record no.: X2020990000413 Denomination of invention: CDK inhibitors Granted publication date: 20160608 License type: Common License Record date: 20200817 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20131204 Assignee: Jiahe biopharmaceutical (Cayman) Holdings Limited Assignor: G1 Therapeutics, Inc. Contract record no.: X2020990000426 Denomination of invention: CDK inhibitors Granted publication date: 20160608 License type: Common License Record date: 20200820 |
|
EE01 | Entry into force of recordation of patent licensing contract |